Not accepting Tequin Antibiotic Case inquiries
We are sorry, but we not accepting case inquiries for Tequin Antibiotic and do not have any recommendations for a firm who is handling Tequin Antibiotic cases.
Bristol Myers Squibb quietly announced that it would no longer manufacture Tequin. Since the FDA did not ban Tequin, Bristol Myers Squibb was only going to cease manufacturing it but would not recall all existing available Tequin in the supply chain. Unfortunately, thousands of additional patients may still be prescribed Tequin. Are you one of them? Or have you or a loved one already suffered from the life threatening Tequin side effects?
In addition to the adverse events associated with Tequin that were reported to the FDA, a study published on March 1 in the New England Journal of Medicine showed that patients receiving Tequin had approximately 17 times the odds of having dangerously high blood sugar and four times the odds of having dangerously low blood sugar compared to patients taking other antibiotics.
Additionally, these blood sugar abnormalities have been noted in clinical trials, post-marketing surveillance studies, case reports, and other studies. Tequin carries a unique risk but has no unique benefits over other similar antibiotics and therefore should not be prescribed. If Tequin is banned, it will be the fifth drug of 13 approved fluoroquinolone antibiotics to be taken off the market because of serious safety problems.
In Canada, researchers studied health records for 1.4 million Ontario residents over age 65. Among them were about 17,000 Tequin patients. Researchers found 788 were hospitalized for excessively low blood sugar and 470 patients hospitalized for excessively high blood sugar within 30 days of taking the antibiotic.
Within that group, there were 61 Tequin recipients with hypoglycemia and 86 with hyperglycemia. Compared with other patients in the group, Tequin recipients had four times the risk of hypoglycemia and 17 times the risk of hyperglycemia.
No other fluoroquinolone antibiotic showed such an unusual risk.